<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/27/11</td>
<td>Stephen B. Howell, MD</td>
<td>UCSD</td>
<td>Introduction to Cancer Therapeutics Development</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>10/5/11</td>
<td>Richard Heyman, PhD</td>
<td>Aragon Pharmaceuticals</td>
<td>Developing Next Generation Anti-hormonal Agents that Target Hormone Resistant Cancers</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>10/11/11</td>
<td>Karen Messer</td>
<td>UCSD</td>
<td>Overview of early phase clinical trials in oncology</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>10/18/11</td>
<td>Trey Ideker</td>
<td>UCSD</td>
<td>Genetic networks in cancer diagnostics and personalized therapy</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>10/25/11</td>
<td>Karen Messer</td>
<td>UCSD</td>
<td>Biomarker driven multi-arm Phase II trial designs in oncology</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/1/11</td>
<td>Sadik Esener</td>
<td>UCSD</td>
<td>Nanotechnology Driven New Capabilities For Cancer Detection and Treatment</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/8/11</td>
<td>Richard Schwab</td>
<td>UCSD</td>
<td>Accessing Primary Human Samples; A Biorepository Perspective</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/10/11</td>
<td>Neil Gibson, PhD</td>
<td>Regulus Pharmaceuticals</td>
<td>Challenges and Opportunities in Cancer Drug Discovery and Development</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/15/11</td>
<td>Robert Mattrey</td>
<td>UCSD</td>
<td>Molecular Imaging Reporters for Cancer Detection and Therapy</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/22/11</td>
<td>Loki Natarajan</td>
<td>UCSD</td>
<td>Design of Phase III trials</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>11/29/11</td>
<td>Don Cleveland</td>
<td>UCSD</td>
<td>New targets related to mitosis</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>12/6/11</td>
<td>Tony Reid</td>
<td>UCSD</td>
<td>Oncology clinical trials: from concept to accrual</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>12/13/11</td>
<td>Shyh-Dar Li</td>
<td>Ontario Institute for Cancer Research</td>
<td>Realizing Personalized Treatments for Cancer: Development of Theranostic Polymeric Nanoparticles</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>12/20/11</td>
<td>George Sen</td>
<td>UCSD</td>
<td>Epigenetic Regulators of Epidermal Stem Cell Self-Renewal and Differentiation</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>01/17/12</td>
<td>Maurizio Zanetti</td>
<td>UCSD</td>
<td>ER stress and cancer cells under the microscope of tumor immunology</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>01/31/12</td>
<td>Lyle Arnold</td>
<td>Bioccept</td>
<td>The Zen of Successful Cancer Diagnostic Commercialization</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>02/21/12</td>
<td>Mitchell Mutz</td>
<td>Amplyx</td>
<td>Chaperonin Targeting to Create More Effective, Less Toxic Chemotherapeutics</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>03/6/12</td>
<td>Ed Maggio</td>
<td>Aegis Pharmaceuticals</td>
<td>Novel Formulations for Non-Invasive Systemic and Nose-to-Brain Delivery of Bioactive Peptides</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>4/24/12</td>
<td>Richard Geary</td>
<td>ISIS Pharmaceuticals</td>
<td>RNA-based Therapeutics in Cancer: Bench to Bedside</td>
<td>Comer Commons</td>
</tr>
<tr>
<td>5/9/12</td>
<td>Steve Worland</td>
<td>Anadys</td>
<td>TBA</td>
<td>Comer Commons</td>
</tr>
</tbody>
</table>